Effect of pre- and post-treatment α-fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study

BMC Surgery

Isidoro Di Carlo⁵  Gaetano Bertino⁶  Filippo Palermo²  Giovanni Mannino³  Maria Concetta Arcerito¹  Maurizio Mannino⁴  Annalisa Ardiri⁶  Adriana Toro⁴ 

[1] University of Catania, Catania, Italy;Department of Internal and Specialist Medicine, Section of Infectious Disease, University of Catania, Garibaldi Hospital, Catania, Italy;Infectious Diseases Unit, Cannizzaro Hospital, Catania, Italy;Department of Surgical Sciences, Organ Transplantation and Advanced Technologies, University of Catania, Cannizzaro Hospital, Via Messina, 829, Catania 95126, Italy;Department of Surgery, Hamad Medical Corporation, Doha, Qatar;Department of Internal Medicine and Systemic Disease, Hepatology Unit, University of Catania, S. Marta Hospital, Catania, Italy

关键词: Survival;    Tumor size;    Alpha-fetoprotein;    Radiofrequency ablation;    Transarterial chemoembolization;    Hepatic resection;    Hepatocellular carcinoma;   

Others  :  863138
DOI  :  10.1186/1471-2482-14-40

 received in 2013-11-24, accepted in 2014-06-27,  发布年份 2014

【 摘 要 】

Background

We evaluated treatment modalities and survival in patients with hepatocellular carcinoma (HCC), by pre-treatment and 3-month post-treatment serum alpha-fetoprotein (AFP) levels and pre-treatment tumor diameters.

Methods

We retrospectively reviewed 57 patients treated for HCC in our department from January 2002 to December 2012, including their sex, type of hepatitis, Child class, pre-treatment tumor size, pre-treatment levels of albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), red blood cells, hemoglobin, and total bilirubin, pre- and 3-month post-treatment serum AFP, and treatment modality (transarterial chemoembolization, resection or radiofrequency ablation). Survival was analyzed at 1, 3, and 5 years after treatment.

Results

The 57 patients included 44 men and 13 women, of whom 44 had hepatitis C virus (HCV) infection, 3 had hepatitis B virus (HBV) infection, 3 had both HBV and HCV infection, 1 had both HBV and hepatitis D virus infection, and 3 had alcohol-related liver cirrhosis. Both pre- and post-treatment serum AFP levels significantly correlated with recurrent tumor size (P < 0.05 for both). Pre-treatment tumor size did not correlate with recurrent tumor size. Patients who underwent hepatic resection survived significantly longer than those who underwent transarterial chemoembolization or radiofrequency ablation (P < 0.05).

Conclusions

Serum AFP level is useful in diagnosing tumor recurrence and predicting prognosis in HCC patients treated by hepatic resection, transarterial chemoembolization, and radiofrequency ablation. Hepatic resection remains the treatment of choice for HCC in suitable patients.

【 授权许可】

   
2014 Toro et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]El-Serag HB: Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007, 37(Suppl 2):S88-S94.
• [2]Arrieta O, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernandez-Pedro N: The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer 2007, 8:28.
• [3]Zhou YM, Yang JM, Li B, Yin ZF, Xu F, Wang B, Xu W, Kan T: Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Hepatobiliary Pancreas Dis Int 2010, 9:33-37.
• [4]Van der Veek PP, de Vos Tot Nederveen Cappel WH, Langers AM, van Hoek B: Two patients with extremely elevated tumor markers: where is the malignancy? Gastroenterol Res Pract 2011, 2011:123743. doi:10.1155/2011/123743. Epub 2011 Jun 16
• [5]Bruix J, Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
• [6]Trapé J, Botargues JM, Porta F, Ricós C, Badal JM, Salinas R, Sala M, Roca A: Reference change value for alpha-fetoprotein and its application in early detection of hepatocellular carcinoma in patients with hepatic disease. Clin Chem 2003, 49:1209-1211.
• [7]Lerose R, Molinari R, Rocchi E, Manenti F, Villa E: Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer 2001, 37:239-245.
• [8]Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, Poulsen H, Tygstrup N: Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984, 4:430-435.
• [9]Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325:675-680.
• [10]Zaman SN, Melia WM, Johnson RD, Portmann BC, Johnson PJ, Williams R: Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985, 1:1357-1360.
• [11]Chan SL, Chan AT, Yeo W: Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment, monitoring or both? Future Oncol 2009, 5:889-899.
• [12]Miyagawa S, Makuuchi M, Kawasaki S, Kakazu T: Criteria for safe hepatic resection. Am J Surg 1995, 169:589-594.
• [13]Terminology Committee of the IHPBA: Terminology of liver anatomy and resections. HPB Surg 2000, 2:333-339.
• [14]Corey KE, Pratts DS: Current status of therapy for hepatocellular carcinoma. Therap Adv Gastroenterol 2009, 2:45-57.
• [15]Li P, Wang SS, Liu H, Li N, McNutt MA, Li G, Ding HG: Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma. World J Gastroenterol 2011, 17:4563-4571.
• [16]Abbasi A, Bhutto AR, Butt N, Munir SM: Corelation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma. J Pak Med Assoc 2012, 62:33-36.
• [17]Yamagiwa K, Shiraki K, Yamakado K, Mizuno S, Hori T, Yagi S, Hamada T, Iida T, Nakamura I, Fujii K, Usui M, Isaji S, Ito K, Tagawa S, Takeda K, Yokoi H, Noguchi T: Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study. J Gastroenterol Hepatol 2008, 23:482-490.
• [18]Wang XW, Xie H: Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci 1999, 64:17-23.
• [19]Li MS, Li PF, He SP, Du GG, Li G: The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol 2002, 8:469-475.
• [20]Li MS, Li PF, Chen Q, Du GG, Li G: Alpha-fetoprotein stimulated the expression of some oncogenes in human hepatocellular carcinoma Bel 7402 cells. World J Gastroenterol 2004, 10:819-824.
• [21]Fujioka M, Nakashima Y, Nakashima O, Kojiro M: Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 2001, 34:1128-1134.
• [22]Yang X, Zhang Y, Zhang L, Zhang L, Mao J: Silencing alphafetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett 2008, 271:281-293.
• [23]Tang H, Tang XY, Liu M, Li X: Targeting alpha-fetoprotein represses the proliferation of hepatoma cells via regulation of the cell cycle. Clin Chim Acta 2008, 394:81-88.
• [24]Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K: Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996, 111:720-726.
• [25]Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000, 89:500-507.
• [26]Tung-Ping Poon R, Fan ST, Wong J: Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 2000, 232:10-24.
• [27]Adachi E, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, Tsuneyoshi M: Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer 1996, 77:2022-2031.
• [28]Tinkle CL, Haas-Kogan D: Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012, 6:207-219.
• [29]Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, Okita K, Omata M, Takayasu K, Yamaoka Y: Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004, 101:796-802.
• [30]Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH, Newman S, Omary R, Abecassis M, Benson AB 3rd, Salem R: Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009, 27:5734-5742.
• [31]Sawhney S, Montano-Loza AJ, Salat P, McCarthy M, Kneteman N, Meza-Junco J, Owen R: Transarterial chemoembolization for hepatocellular carcinoma: significance of extrahepatic collateral supply. Can J Gastroenterol 2011, 25:426-432.
• [32]Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, Dela Torre A, Cho KC, Contractor D, Korogodsky M: Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2003, 197:759-764.
• [33]Hori T, Nagata K, Hasuike S, Onaga M, Motoda M, Moriuchi A, Iwakiri H, Uto H, Kato J, Ido A, Hayashi K, Tsubouchi H: Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol 2003, 38:977-981.
• [34]Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT: Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008, 207:20-29.
• [35]Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, Watanabe T, Mine T, Tokai RFA Study Group: Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer 2010, 116:3638-3644.